Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 466.85M P/E - EPS this Y -4.70% Ern Qtrly Grth -
Income -37.87M Forward P/E -6.59 EPS next Y 3.00% 50D Avg Chg -10.00%
Sales - PEG -0.11 EPS past 5Y - 200D Avg Chg 4.00%
Dividend N/A Price/Book 3.41 EPS next 5Y 73.70% 52W High Chg -33.00%
Recommedations 1.40 Quick Ratio 2.91 Shares Outstanding 59.42M 52W Low Chg 61.00%
Insider Own 2.45% ROA -19.11% Shares Float 43.13M Beta 1.43
Inst Own 60.19% ROE -33.19% Shares Shorted/Prior 2.98M/2.92M Price 7.97
Gross Margin - Profit Margin - Avg. Volume 1,220,874 Target Price 10.00
Oper. Margin - Earnings Date Nov 1 Volume 486,154 Change -0.38%
About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Aldeyra Therapeutics, Inc. News
11/20/24 Top US Penny Stocks To Watch In November 2024
11/19/24 ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
11/18/24 Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
11/14/24 Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
11/12/24 Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year?
10/31/24 Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
10/03/24 Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
09/05/24 Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
09/04/24 High Growth Tech Stocks To Watch In The United States
08/30/24 Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory
08/09/24 Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint
08/08/24 Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
08/07/24 Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
07/31/24 Owning 36% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX),
06/20/24 Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
06/14/24 Aldeyra Therapeutics concludes subject enrolment in dry eye disease trial
06/13/24 Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
06/12/24 Aldeyra Therapeutics to Host Investor Roundtable Q&A
05/29/24 Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
05/14/24 Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
ALDX Chatroom

User Image EMINENZ Posted - 1 hour ago

$ALDX it doesn't get more drerisked than this investment. Should be an easy approval in the bag. Let's climb back to pre CRL levels. Aiming for 7 - 10$.

User Image User123321 Posted - 8 hours ago

$ALDX Gibberish as usual. It will do what it will do despite mostly really bad predictions. But Nonsense away as you like.

User Image Hn1989 Posted - 9 hours ago

$ALDX What are your predictions regarding a potential acquisition? 1. When do you think it might happen? 2. How long would it take to recover the investment after the acquisition? 3. What do you estimate the price range could be (both the highest and the lowest)? Looking forward to hearing your thoughts

User Image LT11 Posted - 12 hours ago

$ALDX https://www.youtube.com/watch?v=rcyACQzHtVE&list=PLCN9tYu3KJvDlsfD1FETmJZPZe-WR7Jw5&index=26&t=484s Not sure how many people have seen this panel, but I’m assuming not that many from the view count. The intent of this video is for the panelist to share some perspective and advice to up in coming bio-pharm startups. There are a few nuggets in here that make this video worth a watch, especially as the panel consists of Todd and a key Abbvie representative, Doug Faunce who is head of Abbvie’s Business Development and Ventures. Doug and Todd have a 10+ year relationship and from the video it seems like Doug is the main reason AbbVie is in partnership with ALDX. Funny enough, Doug was absorbed via the Allergan buyout. Key takeaways that I got from this video as it pertains to AbbVie and ALDX’s relationship. • From a business development standpoint, although AbbVie is always looking for innovative and different therapies, the most important attributes are efficacy, manufacturing feasibility, and marketability.

User Image MontanaT Posted - 12 hours ago

$ALDX starting to feel real healthy again.

User Image GoldmanSlaps Posted - 18 hours ago

$ALDX looking good

User Image TheGodsMustBeCrazy Posted - 21 hours ago

@Milanfinest @rahmanoof I think $ALDX will be worth $750M to $1B (12.59 to 16.79 per share) by mid-April.

User Image TheGodsMustBeCrazy Posted - 21 hours ago

The fact that $ALDX approval can happen months before the pfuda makes the stock un-shortable. Short sellers will start to realize that over next few days and will have to cover their shorts. Stock likely to gap up as a result.

User Image TheGodsMustBeCrazy Posted - 21 hours ago

I agree with @rahmanoof $ALDX could easily get approved in early Feb or even late January, ie months early. $SPRY recently had that experience. They resubmitted their NDA 4-3-2024; were given a PDUFA date that was 6-months post resubmission; but FDA ended up approving them a full TWO MONTHS EARLY. Reason being: FDA team has already reviewed 95% of the NDA (from the first submission review period). Same goes for $ALDX: the FDA team has already reviewed 95% of ALDX's NDA already. Moreover, FDA's CRL said that only deficiency was 1 SINGLE STUDY, &then fda review team THEMSELVES designed the required study for ALDX to conduct to satisfy the CRL. So fda review team can review the new study in a week. This is a classic case where approval is likely to occur MONTHS before the pdufa.People forget this bc people are used to a 1st-round submission where fda almost always takes the full review time allowance. Not so with resubmissions.Ergo: odds of ALDX approval signif before pdufa are VERY high.

User Image TheGodsMustBeCrazy Posted - 22 hours ago

@jaxon613 "It's 6 months, like it is supposed to be- I guess what I am saying is that , that is nothing more special then normal" Nah. What you're saying is not true. $SPRY's resubmitted their NDA, were given a PDUFA date that was 6 months post-resubmission, but FDA ended-up approving the NDA after only ~4 months post resubmission. Which means: FDA sometimes approves a resubmitted nda SIGNIFICANTLY EARLIER than pdufa date. Reason being: the fda review team has already pored over the bulk the NDA materials in-depth during the first submission review period, so they frequently don't need the full 6 months to review the new material. Therefore: $ALDX's NDA could easily get approved MONTHS BEFORE their pdufa of April 2, 2024. we could get a surprise early approval in January or February. After all, the FDA review team were the ones who designed the recent ALDX study which won (p=0.004), so reviewing it should take like 5 nanoseconds.

User Image rahmanoof Posted - 23 hours ago

$ALDX $spry received FDA approval after second NDA 2 months earlier than anticipated PDUFA date . Fruit for thought

User Image TheGodsMustBeCrazy Posted - 1 day ago

Nature is healing. $ALDX

User Image ForExtraBucks Posted - 1 day ago

$ALDX What is cash on hand?

User Image FishingWithDynamite Posted - 1 day ago

$ALDX Another key element to where this is going… On Aldeyra’s website there are currently no openings or job opportunities …. Hmmmm. Make it happen Todd, sign that dotted line with ABBV!!!! Walks like a duck and talks like a duck Hold tight everyone, our day is approaching

User Image LT11 Posted - 1 day ago

$ALDX Interesting little detail I found when browsing linkedin. Saw that David congratulated ALDX's resubmission of the NDA last month. Peep his title and Bio.

User Image GoldmanSlaps Posted - 1 day ago

$ALDX trip down memory lane still holding

User Image All4Retiring Posted - 1 day ago

$ALDX

User Image LT11 Posted - 1 day ago

$ALDX what's everyone PT if Abbvie executes a BO? I'm thinking $1.5B conservatively which would be ~$25 per share..

User Image Kingjake26 Posted - 1 day ago

$ALDX nice day today.

User Image Milanfinest Posted - 1 day ago

$ALDX

User Image steven1x Posted - 1 day ago

$ALDX breaking 5 Tomorrow?

User Image brickross Posted - 1 day ago

@betty123 did they choose to test for 90 minutes? Did they use an artificial chamber to stimulate DED? Did $Aldx show a change in the most important sign? I'm guessing you don't know the answer to any of these.

User Image philipv777 Posted - 1 day ago

$ALDX looking forward to this Jeffries conference tomorrow at 7:30 am. Hopefully some more clarity about what the ‘extension’ means.

User Image MontanaT Posted - 1 day ago

$ALDX

User Image Milanfinest Posted - 1 day ago

$ALDX jesus lord please let s move ciuf ciuf the train leaves the station cmon cmon

User Image jobix Posted - 1 day ago

$ALDX finally started a position here today,waited patiently.

User Image ms1sd Posted - 1 day ago

@Kingjake26 what was the good news today on $ALDX ? Holding significant position.

User Image GoldmanSlaps Posted - 1 day ago

$ALDX last day to buy under 5

User Image Kingjake26 Posted - 1 day ago

$ALDX $AVXL $CAPR $VRNA my favorite 4 long term here. These aren’t a trade. These are investments. I trade the $XBI While holding these four companies. :))

User Image johnnygogogo Posted - 1 day ago

$ALDX wow, $5, also known as the price it was one week ago, also known as 🥱

Analyst Ratings
HC Wainwright & Co. Buy Aug 9, 24
HC Wainwright & Co. Buy Aug 2, 24
Oppenheimer Outperform May 6, 24
HC Wainwright & Co. Buy May 6, 24
Oppenheimer Outperform Apr 3, 24
Citigroup Buy Oct 17, 23
Oppenheimer Perform Oct 17, 23
Oppenheimer Outperform Aug 9, 23
HC Wainwright & Co. Buy Jun 30, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Oct 16 Sell 1.67 2,756,499 4,603,353 8,593,586 10/18/23
Brady Todd C President and CEO President and CEO Sep 07 Option 0.55 273,058 150,182 1,728,343 09/11/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Aug 08 Buy 7.24 97,000 702,280 11,235,085 08/10/22
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Aug 04 Buy 6.17 95,100 586,767 10,997,085 08/08/22
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Aug 01 Buy 5.05 144,185 728,134 10,389,579 08/03/22
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Jul 28 Buy 5.00 119,392 596,960 10,023,271 08/01/22
JOYCE MARTIN JOSEPH Director Director Jun 23 Buy 3.4755 4,323 15,025 23,967 06/27/22
Brady Todd C President and CEO President and CEO Jun 23 Buy 3.3642 17,700 59,546 1,216,535 06/27/22
- - - Jan 11 Buy 8.79 1,050,000 9,229,500 7,335,458 01/11/21